Development and Regulatory Meetings. The Parties agree to meet on a quarterly basis or as reasonably requested by the MPP, to review development and filing status and also regarding such reports concerning Licensed Product and/or the Compound. MPP agrees that information contained in quarterly and other such reports shall be treated as Confidential Information of Licensee; provided, however, that such information may be shared with Shionogi (with Shionogi treating such reports as Confidential Information) and that aggregated data may be publicly disclosed by MPP. Licensee shall, at its own expense and using its own resources, and using all due care in accordance with the prevailing standard of professional competence in a regulatory function in the pharmaceutical industry, obtain, maintain and operate in compliance with
Appears in 5 contracts
Samples: License Agreement, License Agreement, License Agreement